Author:
Yao Xiangyang,Liu Wei,Li Xiaofei,Deng Chenxi,Li Tingdong,Zhong Zhouyue,Chen Shuping,Ge Zhitan,Zhang Xuejie,Zhang Shiyin,Wang Yingbin,Liu Yongliang,Zheng Chao,Ge Shengxiang,Xia Ningshao
Abstract
Abstract
Background
The host blood transcriptional levels of several genes, such as guanylate binding protein 5 (GBP5), have been reported as potential biomarkers for active tuberculosis (aTB) diagnosis. The aim of this study was to investigate whole blood GBP5 protein levels in aTB and non-tuberculosis patients.
Methods
An in-house immunoassay for testing GBP5 protein levels in whole blood was developed, and suspected aTB patients were recruited. Whole blood samples were collected and tested at enrolment using interferon-gamma release assay (IGRA) and the GBP5 assay.
Results
A total of 470 participants were enrolled, and 232 and 238 patients were finally diagnosed with aTB and non-TB, respectively. The GBP5 protein levels of aTB patients were significantly higher than those of non-tuberculosis patients (p < 0.001), and the area under the ROC curve of the GBP5 assay for aTB diagnosis was 0.76. The reactivity of the GBP5 assay between pulmonary and extrapulmonary tuberculosis patients was comparable (p = 0.661). With the optimal cut-off value, the sensitivity and specificity of the GBP5 assay for diagnosing aTB were 78.02 and 66.81%, respectively, while those of IGRA were 77.59 and 76.47%. The combination of the GBP5 assay and IGRA results in 88.52% accuracy for diagnosing aTB in 63.83% of suspected patients with a positive predictive value of 89.57% and a negative predictive value of 87.59%.
Conclusions
Whole blood GBP5 protein is a valuable biomarker for diagnosing of aTB. This study provides an important idea for realizing the clinical application of whole blood transcriptomics findings by immunological methods.
Funder
National Science and Technology Key Project
Natural Science Foundation of Fujian Province
Publisher
Springer Science and Business Media LLC
Reference28 articles.
1. World Health Organization(WHO). Global tuberculosis report 2021. https://doi.org/http://www.who.int/publications/digital/global-tuberculosis-report-2021 . Accessed 14 Oct 2021
2. Sharifi-Rad J, Salehi B, Stojanovic-Radic ZZ, Fokou PVT, Sharifi-Rad M, Mahady GB, et al. RETRACTED: medicinal plants used in the treatment of tuberculosis–ethnobotanical and ethnopharmacological approaches. Biotechnol Adv. 2017. https://doi.org/10.1016/j.biotechadv.2017.07.001.
3. Reid MJ, Shah NS. Approaches to tuberculosis screening and diagnosis in people with HIV in resource-limited settings. Lancet Infect Dis. 2009;9(3):173–84.
4. Lawn SD, Mwaba P, Bates M, Piatek A, Alexander H, Marais BJ, et al. Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test. Lancet Infect Dis. 2013;13(4):349–61.
5. Pai M, Behr MA, Dowdy D, Dheda K, Divangahi M, Boehme CC, et al. Tuberculosis. Nat Rev Dis Primers. 2016;2:16076.
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献